H. LUNDBECK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.32 DKK | +0.54% |
|
-1.79% | +13.92% |
| May. 15 | H LUNDBECK : Q1 beat adds momentum to the recent share price rally |  |
| May. 15 | Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024 |
| Sales 2024 * | 21.09B 3.06B | Sales 2025 * | 22.13B 3.21B | Capitalization | 36.04B 5.22B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.08B 446M | Net income 2025 * | 3.46B 501M | EV / Sales 2024 * | 1.5 x |
| Net cash position 2024 * | 4.47B 648M | Net cash position 2025 * | 8.04B 1.17B | EV / Sales 2025 * | 1.27 x |
| P/E ratio 2024 * |
12.2
x | P/E ratio 2025 * |
10.5
x | Employees | 5,681 |
| Yield 2024 * |
2.4% | Yield 2025 * |
2.76% | Free-Float | 30.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on H. Lundbeck A/S
More press releases
| 1 day | +0.54% | ||
| 1 week | -1.79% | ||
| Current month | +9.64% | ||
| 1 month | +13.09% | ||
| 3 months | +9.89% | ||
| 6 months | +12.95% | ||
| Current year | +13.92% |
1 week
37.00
37.96
1 month
32.3238.72
Current year
31.6238.72
1 year
30.9639.82
3 years
23.3039.84
5 years
23.3039.84
10 years
23.3039.84
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 5 M€ | +14.74% | ||
| 0.02% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 37.32 | +0.54% | 385,549 |
| 24-05-22 | 37.12 | -1.59% | 317,848 |
| 24-05-21 | 37.72 | +0.86% | 378,876 |
| 24-05-17 | 37.4 | +0.43% | 652,440 |
| 24-05-16 | 37.24 | -2.00% | 839,389 |
Delayed Quote Nasdaq Copenhagen, May 23, 2024 at 10:59 am EDT
More quotes
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâs disease, Bipolar disorder, depression, epilepsy, Huntingtonâs disease, Parkinsonâs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâs disease, Azilect for the treatment of Parkinsonâs disease, Xenazine for the treatment of Huntingtonâs disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
37.32
DKK
Average target price
39.96
DKK
Spread / Average Target
+7.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.92% | 5.21B | |
| +20.53% | 72.45B | |
| -4.71% | 23.46B | |
| +4.89% | 8.59B | |
| +7.11% | 8.35B | |
| -23.73% | 7.88B | |
| -0.59% | 4.11B | |
| +7.85% | 4.09B | |
| +20.65% | 3.6B | |
| -1.82% | 2.98B |
- Stock Market
- Equities
- HLUN B Stock
